Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
Aztec Drills 70.1 Meters of 0.80 g/t AuEq (0.49 g/t Au and 16.85 g/t Ag) from Surface in TR26-54 at the Tombstone Project, Arizona
-
Silicon Publishing Launches Prism, Bringing AI-Assisted Automation to Database Publishing
-
Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
-
Aston Bay Announces Pre-Feasibility Study Results and Maiden Mineral Reserve for the Storm Copper Project, Nunavut
-
Electrovaya to Participate in Upcoming Investor Conferences
-
Moderna to Present at Upcoming Conference in November 2026
-
INEO Invited to 15th Annual ROTH Technology Conference in New York
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
-
Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
-
Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
-
Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units
-
Wash100 Award, GovCon Industry's Highest Honor, Opens Nominations for 2027 Season
-
Greene Concepts Highlights Groundwater Resources and Commercial Opportunities
-
SNZweig Forms AEC Industry Advisory Council
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
Medical Care Technologies Inc. (OTCID:MDCE) Subsidiaries to Manage $20 Million in Private Collectibles Assets
-
Opportunistic Trader ETF(WZRD) to Delist and Liquidate
-
LiveOne (Nasdaq: LVO) Releases Preliminary H1 Fiscal 2027 Results: $37.3 Million in Revenue and Record Audio Adjusted EBITDA* of $7.8 Million, Up 619% Year-Over-Year
-
Critics and Listeners Agree: Eylsia Nicolas' "The Wedding Song" Nominated for GlacerFM's Best Pop Song 2026; Second Consecutive Listener's Choice Nomination Follows Widespread Critical Recognition and Growing Global Audience
-
GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents
-
Guard Home Warranty Launches Claims 2.0: A Real US-Based Person in 16 Seconds, Claims Reimbursed Instantly
-
Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.
The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.
Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ET
Dial In:
Domestic callers (toll free): 844-887-9402
International callers: 412-317-6798
Canadian callers (toll free): 866-605-3852
Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=3UkskFxG
A replay of the conference call will be available for 7 days following the conclusion of the call:
Replay for domestic callers (toll free): 877-344-7529, replay access code 7896562
Replay for international callers: 412-317-0088, replay access code 7896562
Replay for Canadian callers (toll free): 855-669-9658, replace access code 7896562
An accompanying slide presentation will be embedded in the webcast (live and replay) and can be accessed under the 'Company Events' section of the Applied DNA investor relations website at https://investors.adnas.com/news-events/company-events/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
For additional information:
Investor Relations: Sanjay M. Hurry, 917-733-5573, [email protected]
Web: https://investors.adnas.com/
SOURCE: Applied DNA Sciences, Inc.
A.Rodriguezv--AMWN